Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Net Equity Issued and Repurchased (2011 - 2016)

Exelixis (EXEL) posted quarterly Net Equity Issued and Repurchased of $37000.0 for Q1 2016, down 99.97% quarter-over-quarter from $145.7 million in Q3 2015.

Analysis

Exelixis (EXEL) Net Equity Issued and Repurchased (2011 - 2016) Analysis & Trends

Exelixis' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $37000.0 for Q1 2016.

  • In Q1 2016, Net Equity Issued and Repurchased changed N/A year-over-year to $37000.0; the TTM figure through Mar 2016 stood at $145.7 million (up 4856366.67% YoY), while the FY2015 annual figure was $145.6 million, up 92.55% from the prior year.
  • Net Equity Issued and Repurchased for Q1 2016 stood at $37000.0, down from $145.7 million in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $145.7 million in Q3 2015, with the low at -$3000.0 in Q4 2014.
  • The 4-year median for Net Equity Issued and Repurchased is $32.5 million (2012), against an average of $47.7 million.
  • Peak annual rise in Net Equity Issued and Repurchased reached 300.0% in 2012, while the deepest fall reached 63.77% in 2012.
  • Exelixis' Net Equity Issued and Repurchased stood at $46000.0 in 2012, then sank by 106.52% to -$3000.0 in 2014, then surged by 4855133.33% to $145.7 million in 2015, then plunged by 99.97% to $37000.0 in 2016.
  • Business Quant data shows EXEL's Net Equity Issued and Repurchased at $37000.0 in Q1 2016, $145.7 million in Q3 2015, and -$3000.0 in Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 141.90 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 37,000.00
Sep 30, 2015 145.65 Mn
Dec 31, 2014 -3,000.00
Mar 31, 2014 75.65 Mn
Jun 30, 2012 46,000.00
Mar 31, 2012 64.99 Mn
Dec 31, 2011 -2,000.00
Jun 30, 2011 -23,000.00
Mar 31, 2011 179.40 Mn